Unknown

Dataset Information

0

Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer.


ABSTRACT: Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge, which is further complicated by the common occurrence of several molecular alterations that confer resistance to standard chemotherapy and targeted agents. Mechanisms of resistance have been identified at multiple levels in the epidermal growth factor receptor (EGFR) pathway, including mutations in KRAS, NRAS, and BRAF V600E, and in the HER2 and MET receptors. These alterations represent oncogenic drivers that may co-exist in the same tumor with other primary and acquired alterations via a clonal selection process. Other molecular alterations include DNA damage repair mechanisms and rare kinase fusions, potentially offering a rationale for new therapeutic strategies. In recent years, genomic analysis has been expanded by a more complex study of epigenomic, transcriptomic, and microenvironment features. The Consensus Molecular Subtype (CMS) classification describes four CRC subtypes with distinct biological characteristics that show prognostic and potential predictive value in the clinical setting. Here, we review the panorama of actionable targets in CRC, and the developments in more recent molecular tests, such as liquid biopsy analysis, which are increasingly offering clinicians a means of ensuring optimal tailored treatments for patients with metastatic CRC according to their evolving molecular profile and treatment history.

SUBMITTER: Martini G 

PROVIDER: S-EPMC7383645 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

altmetric image

Publications

Molecular subtypes and the evolution of treatment management in metastatic colorectal cancer.

Martini Giulia G   Dienstmann Rodrigo R   Ros Javier J   Baraibar Iosune I   Cuadra-Urteaga Jose Luis JL   Salva Francesc F   Ciardiello Davide D   Mulet Nuria N   Argiles Guillem G   Tabernero Josep J   Elez Elena E  

Therapeutic advances in medical oncology 20200724


Colorectal cancer (CRC) is a heterogeneous disease representing a therapeutic challenge, which is further complicated by the common occurrence of several molecular alterations that confer resistance to standard chemotherapy and targeted agents. Mechanisms of resistance have been identified at multiple levels in the epidermal growth factor receptor (EGFR) pathway, including mutations in <i>KRAS, NRAS</i>, and <i>BRAF</i> <sup>V600E</sup>, and in the HER2 and MET receptors. These alterations repre  ...[more]

Similar Datasets

| S-EPMC4879165 | biostudies-literature
| S-EPMC8280229 | biostudies-literature
| S-EPMC10972200 | biostudies-literature
| S-EPMC7281737 | biostudies-literature
| S-EPMC7563268 | biostudies-literature
| S-EPMC5922348 | biostudies-literature
| S-EPMC6738174 | biostudies-literature
| S-EPMC5705494 | biostudies-literature
| S-EPMC4636487 | biostudies-literature
| S-EPMC7286679 | biostudies-literature